<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22068" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gastric Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Menon</surname>
            <given-names>Gopal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>El-Nakeep</surname>
            <given-names>Sarah</given-names>
          </name>
          <aff>Gastroentrology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gopal Menon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah El-Nakeep declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22068.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gastric cancer is a significant global health concern, ranking as the fourth leading cause of cancer deaths and the fifth most frequently diagnosed cancer. The incidence varies by geography, with higher rates in East Asia and a general decline in other regions over the past 3 decades. Risk factors for gastric cancer include <italic toggle="yes">Helicobacter pylori</italic> infection, dietary habits, genetic predispositions, and age. The disease often goes undiagnosed until its advanced stages due to the late onset of symptoms, complicating treatment and lowering survival rates. Diagnosis typically involves endoscopy, which enables tissue sampling and resection of early-stage tumors. Treatment includes gastrectomy, lymphadenectomy, chemotherapy, and, in some instances, targeted therapies or immunotherapies.</p>
        <p>This course enhances the participant&#x02019;s ability to recognize gastric cancer&#x02019;s risk factors, clinical presentations, and appropriate screening methods. Participants learn about the latest diagnostic and treatment strategies, including endoscopy, molecular testing, and emerging therapies. Collaboration with an interprofessional team&#x02014;including gastroenterologists, oncologists, radiologists, and surgeons&#x02014;improves patient outcomes by ensuring comprehensive care. This team-based approach facilitates early detection, precise diagnosis, and tailored treatment plans, improving survival rates and quality of life, particularly for patients with advanced or high-risk disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the key risk factors for gastric cancer, including Helicobacter pylori infection, dietary influences, and genetic predispositions.</p></list-item><list-item><p>Differentiate between the intestinal and diffuse histological types of gastric cancer through clinical, imaging, and histopathological findings.</p></list-item><list-item><p>Apply the current treatment guidelines in managing patients with gastric cancer.&#x000a0;</p></list-item><list-item><p>Screen high-risk populations, particularly those in areas with elevated gastric cancer incidence, using endoscopy and appropriate screening guidelines.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22068&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22068">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22068.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gastric cancer is the fourth leading cause of cancer deaths worldwide and the fifth most frequently diagnosed cancer.<xref ref-type="bibr" rid="article-22068.r1">[1]</xref> The incidence of gastric cancer shows significant geographic variation and has declined over the past 3 decades.<xref ref-type="bibr" rid="article-22068.r2">[2]</xref> Risk factors include dietary habits, genetic syndromes, <italic toggle="yes">Helicobacter pylori</italic>&#x000a0;infection, and age.<xref ref-type="bibr" rid="article-22068.r2">[2]</xref> High-risk populations may benefit from screening programs, although such programs are uncommon in Western countries. Gastric cancer primarily arises in 2 histologic forms: intestinal and diffuse-type cancers.<xref ref-type="bibr" rid="article-22068.r3">[3]</xref>&#x000a0;Gastric cancers are more common in the distal stomach (antrum and body), but proximal gastric cancers are increasing in frequency.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref></p>
        <p>Often, gastric cancer is advanced at diagnosis due to the late onset of symptoms. Endoscopy is the diagnostic test of choice, allowing for visual inspection, tissue sampling, and resection of early tumors.<xref ref-type="bibr" rid="article-22068.r5">[5]</xref> Gastrectomy remains the mainstay of curative treatment, with the extent of gastric resection tailored to tumor location and size. A comprehensive lymphadenectomy is also recommended. Patient outcomes improve with perioperative chemotherapy and potentially with radiotherapy.</p>
        <p>Recently, targeted agents and immunotherapy have significantly improved outcomes in patients with actionable mutations. Despite these advancements, the overall prognosis for gastric cancer remains poor, especially in less developed regions.<xref ref-type="bibr" rid="article-22068.r5">[5]</xref>&#x000a0;Gastroesophageal junction (GEJ) tumors have separate&#x000a0;staging, treatment, and prognosis.&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/21327">Esophageal Cancer</ext-link>," for more information on these malignancies.</p>
      </sec>
      <sec id="article-22068.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Gastric Cancer Risk Factors</bold>
</p>
        <p>Gastric cancers are typically sporadic, but 5% to 10% of cases have a familial or genetic association.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref> The key risk factors for gastric cancer include:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes"><bold>Helicobacter pylori</bold></italic>:&#x000a0;Chronic and recurrent <italic toggle="yes">H&#x000a0;pylori</italic> infections are well-established risk factors for gastric adenocarcinoma. The duration of infection, other risk factors, and host factors likely play significant roles in the pathogenesis.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref>&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22683">Helicobacter Pylori</ext-link>," for more information.</p>
          </list-item>
          <list-item>
            <p><bold>Epstein-Barr virus</bold>: This viral infection has been increasingly noted in association with gastric cancer, usually affecting the proximal stomach.<xref ref-type="bibr" rid="article-22068.r6">[6]</xref>&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/21268">Epstein-Barr Virus</ext-link>," for more information.</p>
          </list-item>
          <list-item>
            <p><bold>Dietary factors</bold>: Risk factors include high salt intake (salt-preserved foods), consumption of N-nitroso compounds, smoking, a diet low in vitamins A and C, high consumption of smoked or cured foods, lack of refrigerated foods, and contaminated drinking water.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Obesity</bold>: A high body mass index increases the risk of proximal gastric and GEJ cancers.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Smoking</bold>: Smoking increases the risk of gastric cancer, particularly in men.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Gastroesophageal reflux</bold>: Chronic reflux is associated with a higher rate of GEJ adenocarcinomas. Additionally, bile reflux into the stomach, as seen in patients after certain gastric surgeries, increases the risk of gastric cancer.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Environmental factors</bold>: Exposure to rubber manufacturing, tin mining, metal processing, and coal increases the risk of gastric cancer.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Host factors</bold>: Individuals with type A blood have approximately a 20% higher incidence of gastric cancer compared to those with blood groups O, B, or AB, particularly with the diffuse type. Pernicious anemia&#x000a0;and chronic atrophic gastritis&#x000a0;increase the risk of intestinal-type gastric cancer up to 6-fold. Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27034">Pernicious Anemia</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22086">Atrophic Gastritis</ext-link>," for more information. Other conditions associated with an increased risk include benign gastric ulcers, hypertrophic gastropathy, and gastric polyps.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Protective factors</bold>: A high intake of fiber, fruits, and vegetables likely provides a protective benefit against gastric cancer.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Genetic associations</bold>: A subset of gastric cancers are associated with genetic syndromes, including:
<list list-type="bullet"><list-item><p>Hereditary nonpolyposis colon cancer has a 13% lifetime risk, predominantly intestinal type. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22817">Hereditary Nonpolyposis Colorectal Cancer</ext-link>," for more information.</p></list-item><list-item><p>Familial adenomatous polyposis has a 10% risk. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/21606">Familial Adenomatous Polyposis</ext-link>," for more information.</p></list-item><list-item><p>Peutz-Jeghers syndrome has a 29% risk.&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/27073">Peutz-Jeghers Syndrome</ext-link>," for more information.</p></list-item><list-item><p>Juvenile polyposis syndrome has a 21% risk.</p></list-item><list-item><p>Li-Fraumeni syndrome is associated with gastric cancer. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/24243">Li-Fraumeni Syndrome</ext-link>," for more information.</p></list-item><list-item><p>Hereditary breast and ovarian cancer syndrome are associated with gastric cancer.</p></list-item><list-item><p>Phosphatase and tensin homolog or hamartoma tumor (Cowden) syndrome are also associated with gastric cancer. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/20079">Cowden Disease</ext-link>," for more information.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22068.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Gastric cancer is the fifth most common and the fourth most lethal malignancy worldwide.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref> Although incidence and mortality rates have declined, they remain significantly higher in low-resource countries and East Asia. In the United States, approximately 26,890 newly detected cases of gastric cancer are expected to be diagnosed in 2024. Gastric cancer is more prevalent among men than women.</p>
        <p>In developed countries, the rate of distal gastric cancers has declined dramatically due to better nutrition, access to clean water, and the early identification and treatment of <italic toggle="yes">H pylori</italic> infection. However, the rates of proximal gastric and GEJ cancers have been increasing. The overall rates of intestinal and diffuse-type gastric cancers have declined, with the decline being more marked for intestinal-type cancers. As a result, diffuse-type cancers now constitute a significant proportion of all gastric cancers. Intestinal-type cancers are more common in men, whereas diffuse-type cancers occur equally in both sexes.<xref ref-type="bibr" rid="article-22068.r7">[7]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22068.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>According to the Lauren classification, gastric adenocarcinoma has 2 main histologic variants.<xref ref-type="bibr" rid="article-22068.r8">[8]</xref> The most common variant is the intestinal type, characterized by gland formation and similar in appearance to other intestinal adenocarcinomas. The less common diffuse-type gastric cancer lacks intercellular adhesion molecules and does not typically have gland formation. Intestinal-type cancers may be associated with signet-ring cells.&#x000a0;</p>
        <p>The molecular drivers for intestinal-type cancers are likely multifactorial. <italic toggle="yes">H pylori</italic> is the most common inciting factor for carcinogenesis, and evidence suggests that these lesions progress from dysplasia to carcinoma over time. Precancerous lesions and conditions predisposing to cancer, such as gastric ulcers, atrophic gastritis, and pernicious anemia, often precede the development of cancer.<xref ref-type="bibr" rid="article-22068.r8">[8]</xref>&#x000a0;In diffuse-type cancers, no defined precancerous lesions have been identified.</p>
      </sec>
      <sec id="article-22068.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Gross Pathology Features</bold>
</p>
        <p>On gross examination, gastric cancer typically presents as a mass or a nonhealing ulcer. Diffuse gastric cancers, however, may lack a noticeable mass due to extensive submucosal infiltration. This extensive infiltration leads to a nondistended stomach characterized by the absence of rugal folds. This distinctive appearance is called "leather bottle stomach" or linitis plastica.<xref ref-type="bibr" rid="article-22068.r9">[9]</xref></p>
        <p>
<bold>Histopathology Findings</bold>
</p>
        <p>Microscopically, the histologic appearance of gastric cancer has traditionally been classified under the Lauren classification, which divides gastric cancers into diffuse-type and intestinal-type tumors (see <bold>Image</bold>. Gastric Carcinoma).<xref ref-type="bibr" rid="article-22068.r10">[10]</xref>&#x000a0;Diffuse-type tumors exhibit markedly aberrant cells with little or no gland formation and occasionally contain signet ring cells (see <bold>Image</bold>.&#x000a0;Diffuse Carcinoma of the Stomach) characterized by cytoplasmic mucin with an eccentrically placed nucleus (see <bold>Images</bold>. Diffuse Gastric Cancer and Signet Ring Carcinoma).&#x000a0;Depending on tumor differentiation, intestinal-type tumors demonstrate gland formation, ranging from well-formed to markedly aberrant glands. Due to the cohesive nature of these cells, they often present as mass lesions.&#x000a0;More recent classifications, eg, the World Health Organization classification, are more detailed and subdivide adenocarcinomas into several distinct subtypes. The impact of these subtypes on overall prognosis remains unclear.</p>
        <p>
<bold>Molecular Pathology</bold>
</p>
        <p>Identifying molecular drivers of carcinoma is increasingly important in determining prognosis and treatment. The Cancer Genome Atlas-based molecular classification&#x000a0;<xref ref-type="bibr" rid="article-22068.r11">[11]</xref> of gastric cancer incorporates molecular diagnostics and clinical and histologic features, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Epstein-Bar Virus-associated</bold>: These tumors, located in the proximal stomach, are characterized by CIMP (CpG island methylator phenotype), mutations in <italic toggle="yes">PIK3CA, ARID1A</italic>, and<italic toggle="yes"> BCOR</italic>, and amplifications of programmed death protein 1 and L2.</p>
          </list-item>
          <list-item>
            <p><bold>Microsatellite instability</bold>: Resulting from defects in mismatch repair genes, these tumors are hypermutated and typically found in more distal cancers.</p>
          </list-item>
          <list-item>
            <p><bold>Genomically stable</bold>: Genomic stability is associated with diffuse-type cancers, which have the lowest overall mutational burden, with mutations in <italic toggle="yes">CDH1</italic> often present.</p>
          </list-item>
          <list-item>
            <p><bold>Chromosomal instability</bold>: Carcinomas with chromosomal instability are the most common group of gastric cancers. They occur in the gastroesophageal junction and cardia and have multiple associated mutations, the most common being <italic toggle="yes">TP53</italic>.</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">HER2</italic> gene amplification</bold>: <italic toggle="yes">HER2</italic> gene amplification is reported in 12% to 27% of gastric cancer cases, with protein overexpression in 9% to 23% of cases. <italic toggle="yes">HER2</italic> positivity, more frequent in the intestinal subtype (33%) compared to the diffuse subtype (8%), has been associated with tumor invasion, lymph node metastasis, and poorer survival. <italic toggle="yes">HER2</italic> testing is recommended for all metastatic gastric cancer, using immunohistochemistry scoring: negative for 0 or 1+, positive for 3+, with reflex fluorescent in situ hybridization for an equivocal 2+ score to confirm (see <bold>Image</bold>.&#x000a0;HER2 Analysis)</p>
          </list-item>
        </list>
        <p>The United States Food and Drug Administration has approved immunotherapy for patients with microsatellite instability in solid tumors, including gastric cancer, allowing the evaluation of immunotherapy potential in patients with metastatic disease who have progressed on standard therapy. Epstein-Bar (EBV)positive gastric tumors generally have a better prognosis, although routine EBV staining is not yet recommended in clinical care.<xref ref-type="bibr" rid="article-22068.r12">[12]</xref><xref ref-type="bibr" rid="article-22068.r13">[13]</xref><xref ref-type="bibr" rid="article-22068.r14">[14]</xref><xref ref-type="bibr" rid="article-22068.r15">[15]</xref><xref ref-type="bibr" rid="article-22068.r16">[16]</xref></p>
      </sec>
      <sec id="article-22068.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Clinical History</bold>
</p>
        <p>Gastric cancer often presents with a variety of symptoms that can be subtle and easily mistaken for less severe conditions in its early stages. Common symptoms include persistent indigestion, stomach discomfort, and a feeling of fullness or bloating after small meals. As the disease progresses, patients may experience more severe symptoms such as unexplained weight loss, persistent nausea or vomiting, difficulty swallowing, and noticeable fatigue. There may be visible signs of gastrointestinal bleeding, such as black or bloody stools, and in advanced stages, a palpable mass in the abdomen. Due to the nonspecific nature of these symptoms, gastric cancer is frequently diagnosed at a later stage, emphasizing the importance of early medical evaluation for persistent gastrointestinal issues. In high-risk populations that undergo screening endoscopy (most commonly seen in Japan and South Korea), gastric cancer is often diagnosed at an early stage.<xref ref-type="bibr" rid="article-22068.r10">[10]</xref>&#x000a0;</p>
        <p>
<bold>Physical Examination Findings</bold>
</p>
        <p>Physical examination findings in gastric cancer are typically evident only in the advanced stages of the disease. These may include an abdominal mass or a dilated stomach suggestive of gastric outlet obstruction. Metastatic gastric cancer can present with several distinctive signs, including the Virchow node (ie, left supraclavicular adenopathy), Sister Mary Joseph node (ie, periumbilical nodule), and Irish node (ie, left axillary node). Direct metastasis to the peritoneum may manifest as a Krukenberg tumor (ovarian mass), Blumer shelf (cul-de-sac mass), ascites (peritoneal carcinomatosis), and hepatomegaly, often indicating a diffuse disease burden.<xref ref-type="bibr" rid="article-22068.r10">[10]</xref>&#x000a0;Paraneoplastic manifestations, although rare and nonspecific to gastric cancer, can include various dermatological conditions (eg, diffuse seborrheic keratosis or acanthosis nigricans), hematological disorders (eg, microangiopathic hemolytic anemia and a hypercoagulable state known as Trousseau syndrome), renal disorders (eg, membranous nephropathy), and autoimmune diseases (eg, polyarteritis nodosa).<xref ref-type="bibr" rid="article-22068.r17">[17]</xref></p>
      </sec>
      <sec id="article-22068.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Diagnostic Evaluation</bold>
</p>
        <p>Patients exhibiting symptoms indicative of gastric cancer should undergo an upper endoscopy as a primary diagnostic tool.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref> Although upper endoscopy is more invasive and costly than traditional barium or gastrografin swallow studies, it offers the critical advantage of direct tissue diagnosis through biopsy of esophageal, gastric, or duodenal lesions. Any suspicious gastric ulcer should be biopsied multiple times to improve diagnostic accuracy significantly; sensitivity increases from approximately 70% with a single biopsy to 98% with 7 biopsies. Meticulous documentation of the lesion's location, size, and characteristics is essential.<xref ref-type="bibr" rid="article-22068.r18">[18]</xref> Advanced techniques such as chromoendoscopy and narrow-band imaging should be utilized if there is a suspicion of more subtle mucosal lesions. Also, multiple mucosal biopsies should be obtained if <italic toggle="yes">H pylori</italic> infection, atrophic gastritis, or other pathologies are suspected. Upper endoscopy has been highly effective in detecting early-stage gastric cancer in high-incidence areas like Japan and South Korea, where it has led to higher cure rates following resection. However, its practice is less common in other regions.</p>
        <p>Following upper endoscopy, an endoscopic ultrasound (EUS) is often warranted for a more detailed assessment of gastric cancer lesions.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref> EUS is instrumental in determining the T stage of the tumor and evaluating the perigastric lymph nodes, which can be biopsied via EUS-guided fine-needle aspiration. The pooled sensitivity and specificity of EUS for distinguishing between T1 and T2 tumors are 0.85 and 0.90, respectively, with confidence intervals of 0.78 to 0.91 and 0.85 to 0.93, respectively. This distinction is crucial, as T1 gastric cancers might be eligible for endoscopic resection. However, the accuracy of EUS is highly dependent on the operator's skill, and less experienced clinicians may have compromised precision in assessing gastric wall invasion.<xref ref-type="bibr" rid="article-22068.r19">[19]</xref></p>
        <p>
<bold>Staging Evaluation</bold>
</p>
        <p>For comprehensive preoperative staging, chest and abdominal imaging are necessary to exclude metastasis and determine surgical resectability.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref> Early abdominopelvic computed tomography (CT) is performed to rule out gross metastatic disease. However, it has limitations in assessing T and N stages and detecting small peritoneal metastases, with an overall accuracy ranging from 42% to 82%. Biopsy of any suspicious solitary or oligometastatic sites should be performed, and paracentesis is recommended if malignant ascites is suspected. Chest CT is preferred over plain radiographs for better evaluation. In cases where initial staging is negative for metastatic disease, positron emission tomography combined with CT may be used to assess resectability. Serum markers, including carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 19-9, and cancer antigen 72-4, have limited diagnostic value and may be elevated due to other conditions.</p>
        <p>Staging laparoscopy with peritoneal washings for cytology is advised for patients with potentially resectable disease before starting chemotherapy.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref>&#x000a0;During diagnostic laparoscopy, up to 40% of patients may be found to have peritoneal disease, detected through direct biopsy or cytology from peritoneal washings, which might not be identified by other preoperative imaging.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref>&#x000a0;Patients with detected peritoneal disease are generally considered to have metastatic disease and typically do not undergo surgery. However, a small number may be candidates for aggressive cytoreduction and intraperitoneal chemotherapy.</p>
      </sec>
      <sec id="article-22068.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment modalities used for treating gastric cancer include endoscopic resection, surgery, chemotherapy, radiation, and targeted therapies. Often, these techniques are combined based on tumor location, stage, and patient-related factors.&#x000a0;Endoscopic techniques are reserved for tumors limited to the mucosa or the very superficial submucosa without high-risk factors. Most patients with tumors greater than T2 or who have any evidence of nodal involvement should undergo perioperative chemotherapy followed by surgery. Patients with advanced or nonresectable tumors should undergo chemotherapy with palliative intent. Radiation is typically reserved for palliation or when surgical resection is inadequate. Each modality is discussed under the relevant section.</p>
      </sec>
      <sec id="article-22068.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses that should be considered when evaluating gastric cancer include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute gastritis</p>
          </list-item>
          <list-item>
            <p>Atrophic gastritis</p>
          </list-item>
          <list-item>
            <p>Bacterial gastroenteritis</p>
          </list-item>
          <list-item>
            <p>Chronic gastritis</p>
          </list-item>
          <list-item>
            <p>Esophageal cancer</p>
          </list-item>
          <list-item>
            <p>Esophageal stricture</p>
          </list-item>
          <list-item>
            <p>Esophagitis</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Peptic ulcer disease</p>
          </list-item>
          <list-item>
            <p>Viral gastroenteritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22068.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>
<bold>Endoscopic Resection for Early Local Disease</bold>
</p>
        <p>Endoscopic techniques for treating gastric cancer include endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). These minimally invasive procedures are utilized for early-stage gastric cancer, mainly when the tumors are confined to the mucosa or superficial submucosa.<xref ref-type="bibr" rid="article-22068.r20">[20]</xref>&#x000a0;EMR involves the removal of the target lesion using a snare device.<xref ref-type="bibr" rid="article-22068.r21">[21]</xref> The snare, often equipped with electrocautery, excises the lesion from the gastric wall. This technique is generally suited for small, well-defined lesions and can be performed either with or without electrocautery, which helps achieve hemostasis and reduce bleeding during the procedure. EMR is typically used for tumors less than 2 cm in diameter confined to the mucosal layer. The procedure offers diagnostic and therapeutic benefits, allowing for the removal and immediate evaluation of the lesion.</p>
        <p>Endoscopic submucosal dissection (ESD) is more sophisticated and complex than EMR. ESD involves dissecting the submucosa around the target lesion using either sharp dissection or cautery.<xref ref-type="bibr" rid="article-22068.r21">[21]</xref> This technique removes larger lesions and those with a more invasive pathology. The procedure starts with creating a submucosal lift, followed by careful dissection of the lesion from the underlying muscle layer. ESD is preferred for lesions that are not amenable to EMR due to their size or depth of invasion. This procedure allows for en-bloc resection, where the entire lesion is removed in 1 piece, which is critical for accurate staging and reducing the risk of local recurrence.&#x000a0;Endoscopic resection is considered a viable therapeutic option when specific criteria are met.<xref ref-type="bibr" rid="article-22068.r21">[21]</xref> These criteria include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lesion size</bold>: The lesion should be &#x0003c;2 cm in diameter.</p>
          </list-item>
          <list-item>
            <p><bold>Histological characteristics</bold>: The lesion should be moderate to well-differentiated, indicating a lower likelihood of aggressive behavior.</p>
          </list-item>
          <list-item>
            <p><bold>Clear margins</bold>: The margins of the resected specimen must be free of cancer cells, ensuring that the tumor has been completely removed.</p>
          </list-item>
          <list-item>
            <p><bold>Absence of high-risk features</bold>: The lesion should not exhibit high-risk features, such as lymphovascular or perineural invasion. These features indicate a higher risk of metastasis and a poorer prognosis.</p>
          </list-item>
        </list>
        <p>Clinicians should note if the tumors extend beyond the superficial submucosa, as tumors that invade the deeper submucosa or beyond are associated with significantly higher rates of lymph node metastasis and are generally not suitable for endoscopic resection alone. When performed by skilled clinicians, endoscopic dissection is typically done as an en-bloc resection, which improves the accuracy of staging and reduces the risk of residual cancer. The success rates of endoscopic resection are high, with 5-year overall survival rates ranging from 84% to 96%, depending on the tumor's depth of invasion and other pathological factors. These rates compare favorably with those for gastrectomy, which can offer up to 98% survival for early-stage disease. However, no randomized controlled trials directly compare endoscopic resection with gastrectomy; therefore, treatment decisions should be based on individual patient factors, tumor characteristics, and available expertise. In summary, endoscopic techniques, including EMR and ESD, provide effective, minimally invasive options for managing early gastric cancer. The choice between EMR and ESD depends on the size, depth, and characteristics of the lesion, as well as the expertise of the performing team.<xref ref-type="bibr" rid="article-22068.r22">[22]</xref><xref ref-type="bibr" rid="article-22068.r23">[23]</xref><xref ref-type="bibr" rid="article-22068.r24">[24]</xref></p>
        <p>
<bold>Gastric Resection</bold>
</p>
        <p>Surgery for gastric cancer has made remarkable advancements over recent decades and remains the only definitive cure for patients without metastatic disease. The integration of perioperative or neoadjuvant chemotherapy before surgical resection has significantly improved survival rates for those with locally advanced gastric cancer. Experts now recommend it for most patients with this stage of disease. For patients with T1a and T1b gastric cancers, where endoscopic resection is not feasible, upfront surgical resection remains the standard approach. For tumors at T2 or higher, diagnostic laparoscopy is often employed to assess peritoneal involvement, including peritoneal biopsies and cytology. This is followed by perioperative chemotherapy, with surgical resection performed upon completion of the chemotherapy regimen. The chemotherapy regimen's choice and duration are individualized based on patient-specific factors detailed in the medical oncology section.<xref ref-type="bibr" rid="article-22068.r10">[10]</xref></p>
        <p>The surgical approach varies depending on the tumor's location within the stomach. The fundamental principles of surgery involve achieving an adequate proximal and distal margin, typically 3 to 5 cm, and performing a complete lymphadenectomy of the perigastric lymph nodes (D2 lymphadenectomy) along with appropriate reconstruction. Distal gastric cancers involving the stomach's antrum or distal body are generally treated with distal subtotal gastrectomy. For tumors located in the proximal body or fundus of the stomach, total gastrectomy is often required. For smaller and less advanced tumors, a proximal gastrectomy may be considered. Gastric reconstruction is typically performed using Roux-en-Y gastrojejunostomy for distal subtotal gastrectomy and Roux-en-Y esophagojejunostomy for total gastrectomy. In addition, feeding jejunostomy tubes may be placed to provide nutritional support post-surgery.<xref ref-type="bibr" rid="article-22068.r10">[10]</xref><xref ref-type="bibr" rid="article-22068.r25">[25]</xref></p>
        <p>The extent of lymphadenectomy has been a subject of extensive debate. D1 lymphadenectomy involves the removal of only the perigastric lymph nodes, whereas D2 lymphadenectomy includes these nodes and those along the major vascular axis surrounding the stomach. Two large trials by the Dutch Cancer Group and the Medical Research Council, which compared D1 with D2 lymphadenectomy, were initially flawed and underpowered to conclusively demonstrate the benefits of D2 lymphadenectomy. However, a long-term follow-up study from the Dutch trial, with a median of 15 years and involving 1078 patients, showed results indicating that D2 lymphadenectomy was associated with reduced locoregional recurrence (12% versus 22%), regional recurrence (13% versus 19%), and gastric cancer-related mortality (37% versus 48%) compared to D1 lymphadenectomy.<xref ref-type="bibr" rid="article-22068.r26">[26]</xref> Despite these benefits, D2 lymphadenectomy was associated with significantly higher operative morbidity (10% versus 4%), complication rates (43% versus 25%), and reoperation rates (18% versus 8%). Nevertheless, advances in surgical techniques, such as spleen-preserving D2 resection, have mitigated some of these risks, making D2 lymphadenectomy the recommended approach for resectable gastric cancer.<xref ref-type="bibr" rid="article-22068.r10">[10]</xref><xref ref-type="bibr" rid="article-22068.r25">[25]</xref></p>
        <p>D3 super-extended lymphadenectomy, which includes periaortic dissection, was studied in the Japan Clinical Oncology Group trial 9501. This approach showed no added survival benefit and was associated with significantly higher perioperative complication rates.<xref ref-type="bibr" rid="article-22068.r27">[27]</xref> Current guidelines recommend sampling at least 15 lymph nodes, which has been shown to provide a survival benefit. Minimally invasive techniques, such as laparoscopic surgery, may be employed by experienced surgeons with outcomes comparable to those of open surgery.<xref ref-type="bibr" rid="article-22068.r4">[4]</xref></p>
        <p>In highly selected patients with gastric cancer and peritoneal metastases and no evidence of other distant metastasis, cytoreduction with or without hyperthermic intraperitoneal chemotherapy may be indicated. Patients should undergo preoperative chemotherapy to ensure that there is no disease progression before undergoing cytoreduction. Phase 3 randomized control trials on the role of cytoreduction and&#x000a0;hyperthermic intraperitoneal chemotherapy are ongoing.<xref ref-type="bibr" rid="article-22068.r28">[28]</xref>&#x000a0;</p>
        <p>For patients with gastric cancer who experience obstruction or uncontrolled bleeding, palliative resection may be necessary. However, chemotherapy and radiation therapy are often effective in managing symptoms and should be considered as first-line palliative treatments. Surgery should be reserved for cases where other modalities fail to provide adequate palliation.</p>
      </sec>
      <sec id="article-22068.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>The role of radiation therapy (RT) in gastric cancer has evolved. Adjuvant chemoradiation was recommended as the treatment of choice in patients who had not undergone preoperative chemotherapy. This was based primarily on the SWOG 9008/INT0116, a randomized phase 3 trial that assigned 556 patients with stages I to III gastroesophageal (20%) or gastric cancers (80%) to receive either surgery alone or surgery followed by adjuvant combined chemoradiotherapy. There was an approximate 20% improvement in survival for the group receiving the combined-modality therapy. The median overall survival in the surgery-only group was 27 months compared with 36 months in the chemoradiation group; the HR for death in the surgery-only arm was 1.35 (95% CI, 1.09 to 1.66; <italic toggle="yes">P</italic> = .005), and relapse HR was 1.52 (95% CI, 1.23 to 1.86; <italic toggle="yes">P</italic>&#x000a0;&#x0003c; .001).<xref ref-type="bibr" rid="article-22068.r29">[29]</xref> The study has been criticized for the meager rate of D1 (&#x0003c;54%) or D2 (&#x0003c;10%) lymph node dissection, which was mandated per protocol. The rate of distant metastasis was not reduced in the adjuvant chemoradiation group (16% versus 18%), suggesting that adjuvant therapy could have mainly compensated for inferior surgery.</p>
        <p>CALGB Intergroup C80101 tried to improve the results obtained with INT0116 protocol regimen therapy by randomly selecting patients with resected gastric or GEJ cancer to receive chemoradiotherapy with epirubicin, cisplatin, 5-fluorouracil. This study was not adequately powered to assess noninferiority and did not demonstrate any outcome difference between both arms. The Korean ARTIST&#x000a0;trial&#x000a0;provided further combined therapy evidence. This trial evaluated the addition of radiation therapy to adjuvant chemotherapy in patients who underwent gastrectomy with D2 lymph node dissection. Patients were randomly selected to receive 6 cycles of chemotherapy with cisplatin and capecitabine (CX) or 2 cycles of CX followed by chemoradiation, followed by 2 more cycles of CX. At a median follow-up of 84 months, neither disease-free survival (DFS) nor overall survival differed between the 2 arms. However, unplanned subsets of patients with node-positive disease and intestinal-type gastric cancer did have a significantly improved DFS with the addition of radiation therapy.<xref ref-type="bibr" rid="article-22068.r30">[30]</xref></p>
        <p>The ARTIST 2 trial sought to clarify this benefit, randomizing patients who underwent a D2 lymphadenectomy to adjuvant chemotherapy alone (S1 alone or S1 with oxaliplatin) or adjuvant chemoradiation. There was no benefit to adding radiation, with 3-year overall survival actually being higher in the chemotherapy arms.<xref ref-type="bibr" rid="article-22068.r31">[31]</xref>&#x000a0;The current role of radiation therapy is mostly in patients who have had inadequate surgery (ie, less than D2 dissection), are unable to tolerate chemotherapy, or in bulky tumors that are symptomatic or those that have local invasion.&#x000a0;</p>
      </sec>
      <sec id="article-22068.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p><bold>Neoadjuvant and Adjuvant Therapy for Locally Advanced Resectable Disease</bold>&#x000a0;</p>
        <p>Surgical resection alone can potentially cure early-stage gastric cancer, with a 5-year overall survival rate of 75% for stage I, declining significantly to 35% for stage II and 25% or less for stage III. Most patients who recur after surgery do so distally, which has focused research on neoadjuvant (preoperative) and adjuvant (postoperative) therapies. Perioperative chemotherapy combines the 2 approaches, with chemotherapy administered before and after surgery.&#x000a0;</p>
        <p>
<bold>Perioperative chemotherapy</bold>
</p>
        <p>Perioperative&#x000a0;chemotherapy aims to downstage primary tumors and regional lymph nodes, increasing the likelihood of long-term curative resections. There is a recommendation for high-risk patients (eg, those with bulky T3/T4 tumors, perigastric nodes, linitis plastica, or positive peritoneal cytology) to avoid unnecessary surgery if metastases appear. The MAGIC trial was a significant study in this area, involving 503 patients with resectable stomach cancer, GEJ cancer, and distal esophagus cancer. The trial compared perioperative chemotherapy (3 preoperative and 3 postoperative cycles of epirubicin, cisplatin, and fluorouracil) to surgery alone, finding significant improvements in median overall survival (36% versus 23% 5-year survival) and progression-free survival for the chemotherapy group. The trial suggested that preoperative treatment was the main contributor to improved outcomes since only 55% of patients completed postoperative therapy.<xref ref-type="bibr" rid="article-22068.r32">[32]</xref> The French FNLCC/FFCD ACCORD trial also reported benefits for perioperative chemotherapy, showing better R0 resection rates, reduced disease-free survival, and lower mortality risk. Conversely, the EORTC trial 40954 failed to show survival benefits due to limited accrual.<xref ref-type="bibr" rid="article-22068.r33">[33]</xref></p>
        <p>The FLOT4-AIO trial compared the FLOT regimen (docetaxel, oxaliplatin, leucovorin, and fluorouracil) to an epirubicin-containing regimen, showing higher pathological complete response rates and less toxicity except for neutropenia in the FLOT regimen. Preliminary results favored the FLOT regimen with a median overall survival of 50 months compared to 35 months for the epirubicin-containing regimen.<xref ref-type="bibr" rid="article-22068.r34">[34]</xref><xref ref-type="bibr" rid="article-22068.r35">[35]</xref> Future research aims to determine the benefits of neoadjuvant chemoradiation over chemotherapy alone. Patients undergoing perioperative chemotherapy are restaged after completing 3 to 4 cycles of chemotherapy. If no evidence of disease progression is noted, then surgery is performed. Most patients then receive postoperative chemotherapy for another 3 to 4 cycles, although this depends on patient tolerance and their recovery from surgery.&#x000a0;</p>
        <p><bold>Adjuvant chemotherapy</bold>&#x000a0;</p>
        <p>Adjuvant chemotherapy is recommended after surgery in patients who have not received preoperative therapy.&#x000a0;Adjuvant chemotherapy alone was evaluated in the Japanese ACTS-GC phase 3 trial with S1 (an oral fluoropyrimidine 80 to 120 mg daily for 4 weeks, repeated every 6 weeks for 1 year) as postoperative D2-resection adjuvant therapy compared to surgery alone in 1059 patients with stage II or III gastric cancer and demonstrated a survival benefit with a 5-year overall survival rate of 72% in the S-1 group and 61% in the surgery only group.<xref ref-type="bibr" rid="article-22068.r36">[36]</xref> Similar results were reported by the Korean phase 3 multicenter CLASSIC trial and in a meta-analysis of several trials, where chemotherapy was associated with a significant overall survival benefit with an HR of 0.85 (95% CI, 0.80 to 0.90) and an improvement in DFS (hazard ratio 0.79; 95% CI, 0.72 to 0.87) versus surgery alone.<xref ref-type="bibr" rid="article-22068.r37">[37]</xref> In general, the adjuvant therapy approach is favored in East Asia, while perioperative chemotherapy, usually with the FLOT regimen, is favored in the West.&#x000a0;</p>
        <p><bold>Palliative Therapy for Locally Advanced Unresectable and Advanced Metastatic Disease</bold>&#x000a0;</p>
        <p>The treatment of unresectable locally advanced gastric cancer typically involves regimens used for advanced metastatic disease. The primary goals of medical therapy for advanced gastric cancer are palliative: to alleviate symptoms, enhance quality of life, and modestly extend survival. Several chemotherapy agents are effective, including fluoropyrimidines (eg, fluorouracil and capecitabine), anthracyclines (eg, epirubicin), platinum compounds (eg, cisplatin, oxaliplatin), taxanes (eg, paclitaxel and docetaxel), irinotecan, and targeted therapies like trastuzumab for <italic toggle="yes">HER2</italic>-positive cancers and ramucirumab, a vascular endothelial growth factor 2 antibody. Combination regimens have a higher response rate (up to 65%) than single-agent therapies (up to 40%).</p>
        <p>Patients eligible for chemotherapy should be tested for <italic toggle="yes">HER2</italic> overexpression. Patients that are HER2-positive can receive trastuzumab combined with chemotherapy (commonly fluoropyrimidine plus platinum). For HER2-negative patients in good health, doublet therapy is recommended over triplet regimens due to the higher toxicity of the latter, which is reserved for select patients with excellent performance status. Older or poor-performance individuals may be treated with single agents like fluorouracil, capecitabine, irinotecan, or low-dose taxanes. Docetaxel and irinotecan have shown benefits in second-line chemotherapy, but no optimal standard of care exists.</p>
        <p>Fluorouracil-based combination trials have established the benefits of adding anthracyclines, platinum agents, or taxanes over older treatments. For example, the German trial compared FLP (fluorouracil, leucovorin, cisplatin) with FLO (fluorouracil, leucovorin, oxaliplatin) and found superior survival with FLO in patients older than 65. The TAX-325 trial demonstrated the superiority of adding docetaxel to cisplatin and fluorouracil (DCF) compared to cisplatin and fluorouracil alone (CF). However, DCF had higher toxicity, including febrile neutropenia, limiting its use to patients with good performance status.<xref ref-type="bibr" rid="article-22068.r38">[38]</xref>&#x000a0;The REAL-2 trial substituted capecitabine for fluorouracil and oxaliplatin for cisplatin, showing that EOX (epirubicin, oxaliplatin, capecitabine) was less toxic and provided modestly more prolonged survival than ECF (epirubicin, cisplatin, fluorouracil). FOLFIRI (fluorouracil, leucovorin, irinotecan) has shown similar efficacy to other regimens with less toxicity, making it an alternative for patients unable to tolerate platinum-based treatments.</p>
        <p>Targeted agents like trastuzumab have shown efficacy in advanced gastric cancer. The ToGA trial added trastuzumab to chemotherapy in HER2-positive individuals, improving median overall survival, progression-free survival, and overall response rate without significant toxicity differences.<xref ref-type="bibr" rid="article-22068.r39">[39]</xref> Consequently, trastuzumab with chemotherapy is the standard for HER2-positive cancers. However, in clinical trials, lapatinib, another <italic toggle="yes">HER2/EGFR</italic> inhibitor, did not show survival benefits. Similarly, cetuximab and panitumumab, targeting <italic toggle="yes">EGFR</italic>, worsened toxicity and overall survival in trials.<xref ref-type="bibr" rid="article-22068.r10">[10]</xref></p>
        <p>Angiogenesis inhibitors have yielded mixed results. In the AVAGAST trial, bevacizumab improved progression-free survival and overall response rate but not overall survival. At the same time, ramucirumab showed modest survival benefits in second-line settings, leading to its approval.&#x000a0;However, adding ramucirumab to first-line therapy did not show benefits.<xref ref-type="bibr" rid="article-22068.r40">[40]</xref>&#x000a0;After first-line chemotherapy failure, second-line options include irinotecan or paclitaxel, which improve overall survival compared to the best supportive care. Radiation therapy can provide symptomatic relief but is rarely used alone. Novel agents under investigation include olaparib, which showed significant benefits in combination with paclitaxel, and pembrolizumab, an anti-programmed death protein-1 antibody showing promising results in programmed death-ligand 1&#x02013;positive tumors. Other promising agents include apatinib and regorafenib, which have demonstrated survival benefits in clinical trials.<xref ref-type="bibr" rid="article-22068.r41">[41]</xref></p>
      </sec>
      <sec id="article-22068.s14" sec-type="Staging">
        <title>Staging</title>
        <p>The American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) Eighth Edition 2017 staging system for gastric cancer (see <bold>Table.</bold>&#x000a0;The American Joint Committee on Cancer Gastric Cancer Staging) stratifies 5-year overall survival (5-y OS) according to pathological stage and intervention (surgery only IA-93.6%, IIA-81.8%, and IIIA-54.2% or with neoadjuvant I-76.5%, II-46.3%, III-18.3%, and IV-5.7%). The following TMN classification is utilized for grading:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>T, Tumor</bold>
<list list-type="bullet"><list-item><p>TX: Primary tumor cannot be assessed</p></list-item><list-item><p>T0: No evidence of primary tumor</p></list-item><list-item><p>Tis: Carcinoma in situ; intraepithelial tumor without invasion of the lamina propria</p></list-item><list-item><p>T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa
<list list-type="bullet"><list-item><p>T1a: Tumor invades the lamina propria or muscularis mucosae</p></list-item><list-item><p>T1b: Tumor invades the submucosa</p></list-item></list>
</p></list-item><list-item><p>T2: Tumor invades the muscularis propria</p></list-item><list-item><p>T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures.</p></list-item><list-item><p>T4: Tumor invades the serosa (visceral peritoneum) or adjacent structures
<list list-type="bullet"><list-item><p>T4a: Tumor invades the serosa</p></list-item><list-item><p>T4b: Tumor invades adjacent structures</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>N, Nodes</bold>
<list list-type="bullet"><list-item><p>NX: Regional lymph nodes cannot be assessed</p></list-item><list-item><p>N0: No regional lymph node metastasis</p></list-item><list-item><p>N1: Metastasis in 1 to 2 regional lymph nodes</p></list-item><list-item><p>N2: Metastasis in 3 to 6 regional lymph nodes</p></list-item><list-item><p>N3: Metastasis in 7 or more regional lymph nodes
<list list-type="bullet"><list-item><p>N3a: Metastasis in 7 to 15 regional lymph nodes</p></list-item><list-item><p>N3b: Metastasis in &#x02265;16 regional lymph nodes</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>M, Metastasis</bold>
<list list-type="bullet"><list-item><p>M0: No distant metastasis.</p></list-item><list-item><p>M1: Distant metastasis present.</p></list-item></list>
</p>
          </list-item>
        </list>
        <table-wrap id="article-22068.table0" position="float" orientation="portrait">
          <caption>
            <title>Table.&#x000a0;The American Joint Committee on Cancer Gastric Cancer Staging</title>
          </caption>
          <table style="width: 558px; height: 1433px;" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>0</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">Tis: Carcinoma in situ; intraepithelial tumor without invasion of the lamina propria</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N0: No regional lymph node metastasis</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IA</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T1: Tumor invades lamina propria, muscularis mucosae, or submucosa</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N0: No regional lymph node metastasis</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IB</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T2: Tumor invades muscularis propria</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N0: No regional lymph node metastasis</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T1: Tumor invades lamina propria, muscularis mucosae, or submucosa</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N1: Metastasis in 1-2 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IIA</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T3: Tumor penetrates subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N0: No regional lymph node metastasis</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T2: Tumor invades muscularis propria</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N1: Metastasis in 1-2 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T1: Tumor invades lamina propria, muscularis mucosae, or submucosa</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N2: Metastasis in 3-6 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IIB</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4a: Tumor invades serosa (visceral peritoneum)</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N0: No regional lymph node metastasis</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T3: Tumor penetrates subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N1: Metastasis in 1-2 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T2: Tumor invades muscularis propria</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N2: Metastasis in 3-6 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T1: Tumor invades lamina propria, muscularis mucosae, or submucosa</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3a: Metastasis in 7-15 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IIIA</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4a: Tumor invades serosa (visceral peritoneum)</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N1: Metastasis in 1-2 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T3: Tumor penetrates subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N2: Metastasis in 3-6 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T2: Tumor invades muscularis propria</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3a: Metastasis in 7-15 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T1: Tumor invades lamina propria, muscularis mucosae, or submucosa</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3b: Metastasis in 16 or more regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IIIB</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4b: Tumor invades adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N0: No regional lymph node metastasis</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4a: Tumor invades serosa (visceral peritoneum)</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N2: Metastasis in 3-6 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T3: Tumor penetrates subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3a: Metastasis in 7-15 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T2: Tumor invades muscularis propria</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3b: Metastasis in 16 or more regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IIIC</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4b: Tumor invades adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N1-N2: Metastasis in 1-6 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4a: Tumor invades serosa (visceral peritoneum)</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3a: Metastasis in 7-15 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4b: Tumor invades adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3a: Metastasis in 7-15 regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4a: Tumor invades serosa (visceral peritoneum)</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3b: Metastasis in 16 or more regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">T4b: Tumor invades adjacent structures</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">N3b: Metastasis in 16 or more regional lymph nodes</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M0: No distant metastasis</td>
              </tr>
              <tr>
                <td style="width: 34.025px;" rowspan="1" colspan="1">
<bold>IV</bold>
</td>
                <td style="width: 230.633px;" rowspan="1" colspan="1">Any T</td>
                <td style="width: 128.992px;" rowspan="1" colspan="1">Any N</td>
                <td style="width: 111.017px;" rowspan="1" colspan="1">M1: Distant metastasis present</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-22068.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of gastric cancer is closely linked to the extent of the tumor, including nodal involvement and direct tumor invasion beyond the gastric wall. Tumor grade may also offer additional prognostic insight. More than 50% of patients with localized distal gastric cancer can achieve a cure. However, early-stage disease constitutes only 10% to 20% of all gastric cancer cases diagnosed in the United States.</p>
        <p>Most patients present with metastatic disease, either regional or distant. The overall 5-year survival rate varies significantly, ranging from nearly 0 for patients with disseminated disease to approximately 50% for those with distal, resectable regional disease. For patients with localized proximal gastric cancer, the 5-year survival rate is only 10% to 15%. Although treatment for disseminated gastric cancer can provide symptomatic relief and some extension of life, long-term remissions are rare.</p>
      </sec>
      <sec id="article-22068.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Gastric&#x000a0;cancer's complications are diverse. Complications related to the primary tumor include bleeding, obstruction, perforation, and fistulization to surrounding organs. Metastatic disease can present with different symptoms based on the site of metastasis. Complications of surgery include bleeding, surgical site and organ space infections, anastomotic leaks, injury to surrounding structures like the&#x000a0;spleen and duodenum, and longer-term complications like incisional hernias. (Please refer to&#x000a0;the<bold>&#x000a0;Medical</bold><bold>&#x000a0;Oncology</bold>&#x000a0;section for more information on the adverse effects of chemotherapy).&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-22068.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Gastric&#x000a0;cancer is the fifth most common malignancy in both men and women and the fourth most common cause of death. Chronic infection with <italic toggle="yes">H. Pylori</italic>, smoking, and obesity are correctable risk factors that individuals should be aware of. Alarm symptoms that require urgent evaluation with an upper endoscopy include upper or lower gastrointestinal bleeding, weight loss, or dysphagia. Those with a strong family history of gastric cancer should begin&#x000a0;screening with upper endoscopy at an early age. Most local and regional diseases are treated with chemotherapy and surgery. Metastatic disease&#x000a0;is best managed with chemotherapy, surgery, and radiation reserved for symptoms or palliation.</p>
      </sec>
      <sec id="article-22068.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with gastric cancer requires a coordinated, collaborative approach among healthcare professionals, including oncologists, surgeons, nurses, pharmacists, and other specialists. Clinicians must have strong skills in diagnosing, evaluating, and treating gastric cancer, interpreting complex imaging, and choosing appropriate treatments. Depending on the cancer's stage, collaboration with gastroenterologists and surgical and radiation oncologists is essential.</p>
        <p>An evidence-based, individualized treatment plan tailored to each patient's needs is crucial. Ethical considerations and respecting patient autonomy must guide treatment decisions. Clearly defined roles and responsibilities within the interprofessional team are critical to ensure that each specialist contributes effectively. Effective communication is necessary to share information, address concerns, and resolve challenges. Coordinated care is vital for managing the patient's journey, from diagnosis to follow-up, to prevent errors, avoid delays, and prioritize patient safety. This comprehensive approach enhances outcomes and ensures patient satisfaction, leading to more effective management of gastric cancer.</p>
      </sec>
      <sec id="article-22068.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22068&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22068">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/gastric-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22068">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22068/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22068">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22068.s20">
        <fig id="article-22068.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Gastric Carcinoma. 10&#x000d7; H/E histologic specimen of gastric cancer. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gastric__tubular__ca03" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22068.s21">
        <fig id="article-22068.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Gastric carcinoma, signet ring type, diffuse gastric cancer. 4x H/E Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="signet__ring__gastric02" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22068.s22">
        <fig id="article-22068.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Signet Ring Carcinoma. Signet ring carcinoma is characterized by cytoplasmic mucin with an eccentrically placed nucleus, 10&#x000d7; H/E. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="signet__ring__gastric04" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22068.s23">
        <fig id="article-22068.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Diffuse Carcinoma of the Stomach. Histologic 4&#x000d7; H/E specimen showing diffuse-type tumors with markedly aberrant cells with little or no gland formation and occasional signet ring cells. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="signet__ring__gastric03" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22068.s24">
        <fig id="article-22068.image.f5" position="float" orientation="portrait">
          <caption>
            <p>HER2 Analysis. Prognostic and predictive HER2 analysis is crucial for gastric cancer treatment. Correct HER2 evaluation can select patients for target treatment. Here, immunohistochemistry is performed and graded as 1+ ("staining is weak or detected in only one part of the membrane of at least 5 cohesive cells"). Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="her204" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22068.s25">
        <title>References</title>
        <ref id="article-22068.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ilic</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of stomach cancer.</article-title>
            <source>World J Gastroenterol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>28</day>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>1187</fpage>
            <page-range>1187-1203</page-range>
            <pub-id pub-id-type="pmid">35431510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thrift</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>El-Serag</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Burden of Gastric Cancer.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>534</fpage>
            <page-range>534-542</page-range>
            <pub-id pub-id-type="pmid">31362118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Pu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Updates on global epidemiology, risk and prognostic factors of gastric cancer.</article-title>
            <source>World J Gastroenterol</source>
            <year>2023</year>
            <month>Apr</month>
            <day>28</day>
            <volume>29</volume>
            <issue>16</issue>
            <fpage>2452</fpage>
            <page-range>2452-2468</page-range>
            <pub-id pub-id-type="pmid">37179585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ajani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bentrem</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Corvera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Enzinger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Enzler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fanta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Farjah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gerdes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Hochwald</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hofstetter</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Ilson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Keswani</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kleinberg</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Klempner</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>QP</given-names>
              </name>
              <name>
                <surname>Matkowskyj</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulcahy</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Outlaw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Pimiento</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Poultsides</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Reznik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roses</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Yakoub</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McMillian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pluchino</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-192</page-range>
            <pub-id pub-id-type="pmid">35130500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lordick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carneiro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cascinu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fleitas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haustermans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Piessen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smyth</surname>
                <given-names>EC</given-names>
              </name>
              <collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab>
            </person-group>
            <article-title>Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1005</fpage>
            <page-range>1005-1020</page-range>
            <pub-id pub-id-type="pmid">35914639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SQ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>583463</fpage>
            <pub-id pub-id-type="pmid">33381453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machlowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baj</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sitarz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maciejewski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sitarz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Jun</month>
            <day>04</day>
            <volume>21</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">32512697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ning</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>XT</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of modified Lauren classification in gastric cancer.</article-title>
            <source>World J Gastrointest Oncol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>15</day>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>1184</fpage>
            <page-range>1184-1195</page-range>
            <pub-id pub-id-type="pmid">34616522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamid</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hamza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rezac</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Linitis Plastica.</article-title>
            <source>S D Med</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>75</volume>
            <issue>8</issue>
            <fpage>375</fpage>
            <pub-id pub-id-type="pmid">36745987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smyth</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grabsch</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>van Grieken</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Lordick</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Gastric cancer.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Aug</month>
            <day>29</day>
            <volume>396</volume>
            <issue>10251</issue>
            <fpage>635</fpage>
            <page-range>635-648</page-range>
            <pub-id pub-id-type="pmid">32861308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Molecular Classification of Gastric Adenocarcinoma.</article-title>
            <source>Gastroenterology Res</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>275</fpage>
            <page-range>275-282</page-range>
            <pub-id pub-id-type="pmid">31803306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Cain</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Gyorkey</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.</article-title>
            <source>Gastroenterology</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-31</page-range>
            <pub-id pub-id-type="pmid">7054024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coit</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Roviello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kassab</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wittekind</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project.</article-title>
            <source>Gastric Cancer</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-225</page-range>
            <pub-id pub-id-type="pmid">26897166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wakelin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Deans</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crofts</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Plevris</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Paterson-Brown</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma.</article-title>
            <source>Eur J Radiol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-7</page-range>
            <pub-id pub-id-type="pmid">11809546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mihmanli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dilege</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Coskun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eroglu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uysalol</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>The use of tumor markers as predictors of prognosis in gastric cancer.</article-title>
            <source>Hepatogastroenterology</source>
            <year>2004</year>
            <season>Sep-Oct</season>
            <volume>51</volume>
            <issue>59</issue>
            <fpage>1544</fpage>
            <page-range>1544-7</page-range>
            <pub-id pub-id-type="pmid">15362797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perniceni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ferraz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Louvet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fuks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gayet</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma.</article-title>
            <source>Dis Esophagus</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>236</fpage>
            <page-range>236-40</page-range>
            <pub-id pub-id-type="pmid">25758761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wanebo</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Chmiel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Osteen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cancer of the stomach. A patient care study by the American College of Surgeons.</article-title>
            <source>Ann Surg</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>218</volume>
            <issue>5</issue>
            <fpage>583</fpage>
            <page-range>583-92</page-range>
            <pub-id pub-id-type="pmid">8239772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ono</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujishiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Uedo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yahagi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ajioka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition).</article-title>
            <source>Dig Endosc</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-20</page-range>
            <pub-id pub-id-type="pmid">33107115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungureanu</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Sacerdotianu</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Turcu-Stiolica</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cazacu</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Saftoiu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic Ultrasound vs. Computed Tomography for Gastric Cancer Staging: A Network Meta-Analysis.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2021</year>
            <month>Jan</month>
            <day>16</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33467164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deprez</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Moons</surname>
                <given-names>LMG</given-names>
              </name>
              <name>
                <surname>O&#x002bc;Toole</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gincul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seicean</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pimentel-Nunes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Esparrach</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Polkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vieth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moreels</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Nieveen van Dijkum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>van Hooft</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.</article-title>
            <source>Endoscopy</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-429</page-range>
            <pub-id pub-id-type="pmid">35180797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landin</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Guerr&#x000f3;n</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection.</article-title>
            <source>Surg Clin North Am</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>100</volume>
            <issue>6</issue>
            <fpage>1069</fpage>
            <page-range>1069-1078</page-range>
            <pub-id pub-id-type="pmid">33128880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic treatment for early gastric cancer.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>28</day>
            <volume>20</volume>
            <issue>16</issue>
            <fpage>4566</fpage>
            <page-range>4566-73</page-range>
            <pub-id pub-id-type="pmid">24782609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gotoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sasako</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.</article-title>
            <source>Gastric Cancer</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-225</page-range>
            <pub-id pub-id-type="pmid">11984739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer.</article-title>
            <source>Endoscopy</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>784</fpage>
            <page-range>784-93</page-range>
            <pub-id pub-id-type="pmid">26111362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barreto</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Sirohi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Why should we perform a D2 lymphadenectomy in gastric cancer?</article-title>
            <source>Future Oncol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>23</issue>
            <fpage>2009</fpage>
            <page-range>2009-2012</page-range>
            <pub-id pub-id-type="pmid">28984466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Songun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Putter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kranenbarg</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sasako</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van de Velde</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2010</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>439</fpage>
            <page-range>439-49</page-range>
            <pub-id pub-id-type="pmid">20409751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasako</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nashimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kurita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hiratsuka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsujinaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okajima</surname>
                <given-names>K</given-names>
              </name>
              <collab>Japan Clinical Oncology Group</collab>
            </person-group>
            <article-title>D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Jul</month>
            <day>31</day>
            <volume>359</volume>
            <issue>5</issue>
            <fpage>453</fpage>
            <page-range>453-62</page-range>
            <pub-id pub-id-type="pmid">18669424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugarbaker</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Van der Speeten</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant HIPEC for gastric cancer.</article-title>
            <source>J Gastrointest Oncol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>Suppl 1</issue>
            <fpage>S18</fpage>
            <page-range>S18-S19</page-range>
            <pub-id pub-id-type="pmid">33970159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smalley</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hundahl</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Ajani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gunderson</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martenson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stemmermann</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Blanke</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Jul</month>
            <day>01</day>
            <volume>30</volume>
            <issue>19</issue>
            <fpage>2327</fpage>
            <page-range>2327-33</page-range>
            <pub-id pub-id-type="pmid">22585691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Noh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Jan</month>
            <day>20</day>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-73</page-range>
            <pub-id pub-id-type="pmid">22184384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>WK</given-names>
              </name>
              <collab>ARTIST 2 investigators</collab>
            </person-group>
            <article-title>A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>&#x02606;</sup>.</article-title>
            <source>Ann Oncol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>368</fpage>
            <page-range>368-374</page-range>
            <pub-id pub-id-type="pmid">33278599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allum</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Stenning</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Van de Velde</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Nicolson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarffe</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lofts</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Iveson</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weeden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>MAGIC Trial Participants</surname>
              </name>
            </person-group>
            <article-title>Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Jul</month>
            <day>06</day>
            <volume>355</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">16822992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ychou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boige</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pignon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Conroy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bouch&#x000e9;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lebreton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ducourtieux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bedenne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fabre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Saint-Aubert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gen&#x000e8;ve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lasser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>May</month>
            <day>01</day>
            <volume>29</volume>
            <issue>13</issue>
            <fpage>1715</fpage>
            <page-range>1715-21</page-range>
            <pub-id pub-id-type="pmid">21444866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Batran</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Homann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pauligk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goetze</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Meiler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haag</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Luley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lindig</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schmiegel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stoehlmacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Folprecht</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prasnikar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fischbach</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mahlberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trojan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koenigsmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Thuss-Patience</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Illerhaus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moehler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schenk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kullmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Behringer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Heike</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pink</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Teschendorf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>L&#x000f6;hr</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bernhard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schuch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rethwisch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>von Weikersthal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schulmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weniger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaiser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oduncu</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>G&#x000fc;ntner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hozaeel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Reichart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000f6;nig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bechstein</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmalenberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hofheinz</surname>
                <given-names>RD</given-names>
              </name>
              <collab>FLOT4-AIO Investigators</collab>
            </person-group>
            <article-title>Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>May</month>
            <day>11</day>
            <volume>393</volume>
            <issue>10184</issue>
            <fpage>1948</fpage>
            <page-range>1948-1957</page-range>
            <pub-id pub-id-type="pmid">30982686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Batran</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hofheinz</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Pauligk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Haag</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Luley</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Meiler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Homann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lorenzen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmalenberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koenigsmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prasnikar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Caca</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trojan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischbach</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mahlberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Illerhaus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zirlik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Behringer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Schmiegel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heike</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ronellenfitsch</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bechstein</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nigsrainer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaiser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schirmacher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hozaeel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Reichart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goetze</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Sievert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>M&#x000f6;nig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tannapfel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>1697</fpage>
            <page-range>1697-1708</page-range>
            <pub-id pub-id-type="pmid">27776843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakuramoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sasako</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nashimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Higashino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kurita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>K</given-names>
              </name>
              <collab>ACTS-GC Group</collab>
            </person-group>
            <article-title>Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Nov</month>
            <day>01</day>
            <volume>357</volume>
            <issue>18</issue>
            <fpage>1810</fpage>
            <page-range>1810-20</page-range>
            <pub-id pub-id-type="pmid">17978289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noh</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <collab>CLASSIC trial investigators</collab>
            </person-group>
            <article-title>Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>1389</fpage>
            <page-range>1389-96</page-range>
            <pub-id pub-id-type="pmid">25439693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moiseyenko</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Tjulandin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Majlis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Constenla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fodor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Voznyi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Risse</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Ajani</surname>
                <given-names>JA</given-names>
              </name>
              <collab>V325 Study Group</collab>
            </person-group>
            <article-title>Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Nov</month>
            <day>01</day>
            <volume>24</volume>
            <issue>31</issue>
            <fpage>4991</fpage>
            <page-range>4991-7</page-range>
            <pub-id pub-id-type="pmid">17075117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Feyereislova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sawaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lordick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ohtsu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omuro</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aprile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kulikov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lehle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000fc;schoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>YK</given-names>
              </name>
              <collab>ToGA Trial Investigators</collab>
            </person-group>
            <article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Aug</month>
            <day>28</day>
            <volume>376</volume>
            <issue>9742</issue>
            <fpage>687</fpage>
            <page-range>687-97</page-range>
            <pub-id pub-id-type="pmid">20728210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohtsu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rha</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Sawaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Starnawski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>Oct</month>
            <day>20</day>
            <volume>29</volume>
            <issue>30</issue>
            <fpage>3968</fpage>
            <page-range>3968-76</page-range>
            <pub-id pub-id-type="pmid">21844504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22068.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilson</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Advances in the treatment of gastric cancer.</article-title>
            <source>Curr Opin Gastroenterol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>465</fpage>
            <page-range>465-468</page-range>
            <pub-id pub-id-type="pmid">30303856</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
